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It is well recognized that the onset of pregnancy is accompanied by changes in maternal physiology that affect the absorption, distribution, metabolism, and elimination of several medications (Loebstein et al., 1997) . These changes include, but are not limited to, increased body water, increased gastric and intestinal emptying time, decreased concentration of plasma albumin, increased production of pro-gestational hormones that may alter the activity of hepatic metabolizing enzymes (Jeong, 2010) , increased hepatic blood flow, and increased renal plasma flow. Since BUP binding to plasma proteins is relatively low (80%) (Findlay et al., 1981) and its high lipophilicity suggests preferential distribution into the tissue over the water compartment, changes in body water and concentrations of plasma albumin are not likely to significantly affect BUP disposition. On the other hand, BUP is extensively metabolized (Schroeder, 1981) and pregnancy-induced increases in hepatic blood flow, along with the changes in hepatic enzyme activity, may alter BUP metabolism, thus affecting maternal plasma drug concentration, and consequently, fetal exposure. Although the effect of pregnancy on the activity of CYP2B6-the primary hepatic enzyme catalyzing hydroxylation of BUP (Hesse et al., 2000) -had not been reported, analysis of the data obtained from in vitro and some in vivo investigations suggests increased activity of CYP2B6 during pregnancy (Dickmann and Isoherranen, 2013) . For example, it was demonstrated that estradiol-one of the steroid hormones secreted during pregnancy by the placenta-induces CYP2B6 mRNA activity and expression in human hepatocytes (Dickmann and Isoherranen, 2013; Choi et al., 2013) . Data obtained from rodent
5 studies also demonstrated that estradiol can induce the expression of CYP enzymes (Nemoto and Sakurai, 1995) . Furthermore, the increased clearance of efavirenz and methadone during pregnancy as compared to the postpartum period (Cressey et al., 2012; Pond et al., 1985; Wolff et al., 2005) , two drugs which are mainly metabolized by hepatic CYP2B6, also suggest increased activity of the enzyme. However, to date, the effect of pregnancy on the hydroxylation of bupropion-which is considered a CYP2B6 probe-substrate-has not been reported.
Due to ethical and safety concerns associated with drug development for the pregnant patient, an alternative approach is the use of an animal model that best simulates drug metabolism and placentation in humans. The use of non-primate animal models to study drug disposition in vivo has certain advantages (e.g., short gestation and lower expense).
Nevertheless, distinct differences in placental development, structure, and functions, as well as revealed interspecies differences in the biotransformation of BUP between rats, mice and humans, (Suckow et al., 1986 ) may present some limitations.
During the last 7 years, we have been studying drug disposition during pregnancy using baboons as a non-human primate animal model (Zharikova et al., 2007; Yan et al., 2008) because of similarities to humans in placental structure and function (Houston, 1969) , as well as in fetal development (Enders et al., 1997) . Furthermore, recent in vitro data obtained in our laboratory revealed similarities between baboons and humans in the biotransformation of BUP by both hepatic and placental microsomes 2011) . The major metabolites formed by human and baboon hepatic and placental microsomes were hydroxybupropion (OH-BUP), threohydrobupropion (TB) and erythrohydrobupropion (EB). OH-BUP was the main metabolite formed by human and baboon hepatic microsomes and hydroxylation of bupropion was catalyzed by CYP2B6 and CYP2B, respectively (Hesse et al., 2000; Wang et al., 2011) . On the other hand, in human and baboon placental microsomes, the main metabolites formed were TB and EB. Furthermore, 11β-hydroxysteroid dehydrogenases were identified as the major
carbonyl-reducing enzymes responsible for the reduction of bupropion to TB and EB in human and baboon microsomal fractions 2011) . These data support, in part, the use of baboons to study BUP disposition during pregnancy.
Since maternal drug concentration is one of the major determinants of fetal drug concentration, it is important to investigate the relationship between maternal exposure to BUP and its active metabolites during different gestational periods. Therefore, the goal of this investigation was to determine the biotransformation of BUP in baboons during pregnancy and postpartum, as well as fetal exposure to the drug and its metabolites after intravenous administration. Urine samples were collected over 24 hours between 0-2, 2-4, 4-8, and 8-24-hour intervals and stored at -70 0 C until analysis. All urine output was collected, the volume was noted, and a 10 ml sample was taken and frozen for later analysis.
Neonatal and maternal blood samples were collected for three mother-neonate pairs immediately after newborn delivery by cesarean section approximately 1 hour after the BUP injection. All blood was centrifuged immediately and plasma was stored at -70 0 C until analysis.
Plasma sample preparation
Plasma samples (100 µL) containing the deuterium-labeled internal standards ( 
Determination of glucuronides of BUP and OH-BUP in urine samples
The concentrations of glucuronidated metabolites of BUP in urine samples were calculated from the difference between the concentrations of nonconjugated (free) and total drug. The total concentrations of BUP and OH-BUP were determined by enzymatic hydrolysis of glucuronidated conjugates as follows: a 100 µL aliquot of baboon urine was incubated with 50 µL of β-glucuronidase (2000 units/mL in PBS buffer, pH 5.0) at 37°C for 4 hours. After incubation, each sample was processed according to the method described above and analyzed by LC-MS/MS to determine the total drug concentration.
Instrumental and analytical conditions
Plasma concentrations of BUP, OH-BUP, TB and EB were determined using a validated LC-MS/MS method previously described from our laboratory (Wang et al., 2012) . The method was partially validated using baboon plasma for specificity, matrix effect, linearity, sensitivity, precision, and accuracy according to the US Food and Drug Administration guidelines (FDA, 2001 ). The calibration curve exhibited linearity within the tested ranges (R 2 >0.99), and the lower limit of quantification (LLOQ) was set as the lowest concentration of the calibration curves (for BUP and OH-BUP, 0.8 ng/ml; for EB and TB, 0.25 ng/ml). Intra-day accuracy of the method ranged between 99% and 106% with precision < 10% for high, medium, low and LLOQ quality control standards. The extraction efficiency of BUP and its metabolites from baboon plasma samples ranged between 90% and 98% with variation < 13%. The matrix factor of BUP and its
metabolites in five individual plasma samples ranged between 94% and 110% with variation < 5%.
The analysis of BUP and its three metabolites was achieved by an Agilent HPLC 1200 series system coupled with an API 4000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA). The HPLC system consisted of a degasser (G1379B), binary pump delivery system (G1312A), Hip-ALS auto-sampler (G1376B) and column compartment (Table 1) .
Pharmacokinetic analysis
Pharmacokinetic analyses were conducted using Kinetica software version 5.0 (Thermo Scientific, Waltham, MA, USA). All data were evaluated using a model independent approach.
Maximum plasma drug concentration (C max ) and time to C max (t max ) were determined by visual inspection of the plasma concentration versus time profile. The area under the plasma concentration versus time curve (AUC 0-∞ ) was determined using the log-linear trapezoidal rule.
The clearance (CL) was calculated as the dose divided by AUC 0-∞ . The in vivo activity of baboon enzymes responsible for biotransformation of BUP was described by the ratio of AUC metabolite to AUC parent drug.
Statistical analysis
Standard descriptive statistics were used to summarize the data. All reported values are expressed as mean ± s.d. Comparisons of pharmacokinetic parameters between pregnant and non-pregnant states (using postpartum data for each animal) were performed by repeated measures ANOVA and considered significant if P <0.05, followed by Tukey-Kramer multiple comparison tests using NCSS statistical software (version 9.0.13, Kaysville, UT).
Results
The mean age of the pregnant baboons (n=5) was 8.8 ± 1.9 years. The average baboon prepregnancy weight was 15.8 ± 1.2 kg (13.9 -17.8). The average baboon weight was 15.3 ± 0.5 kg (14.5 -15.6) at mid-pregnancy, 15.7 ± 0.9 kg (14.9 -16.7) in late pregnancy, 16.1 ± 0.91 kg (15.1 -17.4) at the time of C-section, and 14.8 ± 0.8 kg (13.8 -15.6) postpartum. Thus, the body weight of pregnant baboons remained relatively stable throughout the pregnancy. The plasma concentrations of BUP and OH-BUP were determined in all five baboons during mid-and late pregnancy as well as in the postpartum period. However, in two of the fifteen studies, data were excluded from PK analysis due to deviations from the experimental protocol (animal #1, late pregnancy and animal #2, mid-pregnancy). Since the same site was used for drug dosing and blood sampling, in order to avoid specimen contamination by residual drug concentration after each injection, the line was flushed with at least 10 ml of saline. However, in the two aforementioned cases, incomplete flushing led to residual retention of BUP in the sampling line.
In a third study (animal #5, mid-pregnancy), an error precluded the determination of the plasma sample at the 5-minute time point. Therefore, the C max value is not reported in this case, but all other PK parameters from that study were calculated. Plasma concentrations of TB and EB during gestation as well as in the postpartum period could be determined only in three and two baboons, respectively. In the other animals, plasma concentrations of TB and EB were below the LLOQ, which precluded full analysis.
Bupropion. The individual pharmacokinetic parameters of BUP in pregnant and postpartum baboons are presented in Table 2 . for which data were available in all three gestational periods did not reveal any significant differences (P=0.060 and 0.078 for clearance and AUC 0-∞ , respectively). Relative to the nonpregnant state (postpartum), the average values of BUP clearance during mid-pregnancy and late pregnancy were 25% and 22% higher, respectively. The mean cumulative urinary excretion of unchanged BUP within 24 hours during mid-and late pregnancy was 2.9-and 5.8-fold that of non-pregnant baboons, respectively (Figure 2 ).
Hydroxybupropion. The individual pharmacokinetic parameters of OH-BUP calculated at
different stages of baboon pregnancy and in the postpartum period are presented in Table 3 .
Following a single dose of BUP in pregnant and non-pregnant baboons, peak plasma concentrations of OH-BUP occurred approximately 0.6 hours after bolus injection of the drug. As was observed for the parent drug, the mean values of C max and AUC 0-∞ trended lower in pregnant than in non-pregnant baboons. Relative to the postpartum period, the average C max and AUC 0-∞ values during mid-pregnancy were reduced by 38% and 46%, respectively, and during late pregnancy by 47% and 36%, respectively.
The mean cumulative urinary excretion of total OH-BUP within 24 hours in non-pregnant and pregnant baboons ranged from 2.7-to 7.9-fold higher than the excretion of unchanged BUP (Figure 2 ). Furthermore, during late pregnancy, the mean cumulative urinary excretion of nonglucuronidated OH-BUP was significantly higher than the excretion of bupropion or glucuronidated OH-BUP (3.9-and 6.9-fold higher, respectively, P < 0.05). With the exception of animal #4, the ratio of AUC OH-BUP to AUC BUP in pregnant animals was lower than in the non- during mid-pregnancy and late pregnancy were decreased by 28% and 20%, respectively (Table 4) .
Threohydrobupropion and Erythrohydrobupropion. The individual pharmacokinetic
parameters of TB and EB in pregnant and postpartum baboons are presented in Tables 5 & 6 .
In several instances, the plasma concentrations of TB and EB determined in baboons were below the lower limit of quantification, suggesting that the formation of these reduced metabolites in baboons after an intravenous bolus dose of BUP is minimal.
Neonatal exposure to bupropion and its metabolites. The mean ratios of neonatal/maternal plasma concentrations of BUP and OH-BUP were 0.89 ± 0.18 and 0.24 ± 0.10, respectively (Table 7) . The ratios for TB and EB fell within this same range (0.43 and 0.21, respectively); however, the degree of inter-animal variability was markedly higher for these minor metabolites.
Discussion
Recognizing that pregnancy can alter the pharmacokinetics of medications, and that BUP is extensively metabolized, it is important to compare maternal exposure to BUP during different terms of gestation and postpartum. Therefore, a goal of the current investigation was to determine the biotransformation of BUP in baboons during pregnancy. To minimize the impact of pharmacogenetic variations on the findings, the study was conducted in a longitudinal fashion with each baboon serving as its own control.
In this investigation, pregnant baboons received a single 1 mg/kg i.v. bolus dose of BUP during mid-pregnancy, late pregnancy, and 6 weeks postpartum. The major metabolite determined in the baboons' plasma was OH-BUP. Previously, we reported that in baboons CYP2B was the major hepatic enzyme responsible for the hydroxylation of BUP in vitro (Wang et al., 2011) . Following intravenous administration of 1 mg/kg of BUP, the peak plasma concentration of OH-BUP in non-pregnant baboons was approximately 3-fold less than the peak level of the parent drug. The observed peak plasma concentration of OH-BUP relative to BUP in this study was comparable to its formation in guinea pigs following administration of the drug by the same i.v. route and at a similar concentration (Kiptoo et al., 2009) . However, the formation of reduced metabolites of bupropion (TB and EB) was very low (Tables 5 & 6 ). In some cases, the concentrations of TB and EB in baboon plasma were below the lower limit of quantification, suggesting that after an intravenous bolus dose of BUP, the reduction pathway plays a minor role in the baboon's biotransformation of BUP. In humans, for whom BUP is always administered orally, the plasma concentrations of OH-BUP and TB are 7-10-and 5-fold higher, respectively, than that of the parent compound, while the concentration of EB is similar to that of BUP . While the observed lower formation of OH-BUP, TB, and EB in baboons following i.v. administration of bupropion vs. their formation in humans following oral dosing could be route-dependent, interspecies differences cannot be excluded. Suckow et al.
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reported differences in the biotransformation of bupropion among rats, mice and guinea pigs following intraperitonial (i.p.) administration-a route which involves the first-pass effect and thus the PK of substances are more similar to those seen after oral administration (Suckow et al., 1986) . In rats, the formation of OH-BUP and TB was very low. In mice, although the AUC of OH-BUP was approximately 5-fold higher, the AUC of TB was 2-fold lower than the AUC of bupropion. However, in guinea pigs, the AUCs of both OH-BUP and TB were higher than the AUC of the parent drug (Suckow et al., 1986) .
We observed that BUP clearance during baboon pregnancy trended higher than in the postpartum period (Table 2) (Table 3) . Furthermore, the AUC OH-BUP to AUC BUP ratio was not significantly different when comparing pregnant versus non-pregnant baboons (Table 4) Another factor affecting the pharmacokinetics of bupropion is urinary excretion of the parent drug and its metabolites during late pregnancy. Indeed, the mean urinary excretion of OH-BUP during late pregnancy was 6.7-fold higher than postpartum. The urinary excretion of unchanged BUP also trended higher during pregnancy, being 2.9-and 5.8-fold greater in mid-and late pregnancy, respectively. The increased rates of excretion of BUP and OH-BUP suggest the influence of pregnancy-induced increases in the glomerular filtration rate. In humans, increases in renal plasma flow and glomerular filtration rate also occur as early as the middle of the first trimester (Davison, 1984) . In baboons, we observed that the mean creatinine clearance (as a surrogate marker for glomerular filtration rate) was higher during mid-pregnancy compared to postpartum (30.9 ± 3.9 mL/min vs. 23.9 ± 2.9 mL/min, n=3, P<0.05).
The ratios of AUC OH-BUP to AUC BUP trended lower in pregnant baboons as compared to nonpregnant, except for one animal (Table 4) . It is possible that the hepatic clearance of BUP increases due to an increase in hepatic arterial blood flow. Nevertheless, the plasma AUC OH-BUP may not be higher due to enhanced renal elimination of this metabolite during pregnancy. The increased elimination of OH-BUP during baboon pregnancy may consequently overshadow any pregnancy-induced increase in the hydroxylation of BUP. We also cannot rule out the possible formation of other baboon-specific metabolites beyond OH-BUP, EB, and TB.
BUP and its three metabolites were determined in neonatal plasma (Table 7) BUP and OH-BUP after 1 hour of BUP injection were 0.89 ± 18 and 0.24 ± 0.10, respectively.
Previously, we reported the transfer of BUP and OH-BUP across the dually perfused human placental lobule (Earhart et al., 2010; Hemauer et al., 2010) . After 1 hour of BUP perfusion, the concentration of BUP in the fetal circuit in vitro was 24 ± 3% of its initial concentration in the maternal circuit and the fetal to maternal ratio was 0.68 ± 0.15, which agrees with the data obtained in this investigation.
It should be noted here that while the maternal plasma concentration of BUP in baboons after cesarean section (approximately 1 hour after drug administration) was comparable to its concentration determined during the same time interval in late pregnancy, maternal plasma concentrations of OH-BUP, TB and EB were at least 2-fold higher. This observed difference in maternal concentrations of metabolites could be explained by the reduced renal excretion of more polar compounds due to the use of the inhalation anesthetic isoflurane during surgery (Burchrdi and Kaczmarczyk, 1994) . This could lead to an overestimation of maternal concentrations of OH-BUP, TB and EB, and consequently, an underestimation of the neonatal to maternal concentration ratios. On the other hand, the plasma concentration of BUP was less affected because one hour after BUP administration, the main component of its total clearance would be biotransformation. Furthermore, despite higher maternal concentrations of OH-BUP than BUP 1 hour after the dose, the concentration of OH-BUP in the neonatal plasma was lower than that of BUP, suggesting lower permeability of OH-BUP across baboon placenta. In part, these data could be explained by differences in physicochemical properties between the parent drug and its metabolite. Thus, the presence of the hydroxyl group and consequent hydrogen bonding can lead to a decreased diffusivity of OH-BUP across the placenta as compared to BUP (Kiptoo et al., 2009) .
Due to the wide inter-individual variability between baboons in the biotransformation of bupropion and the number of animals involved in this study, the power of the statistical analysis
of the data was limited. Nevertheless, it appears that maternal exposure to BUP and its major active metabolite OH-BUP is decreased during baboon pregnancy. While the observed increase in the clearance of BUP during baboon pregnancy could be caused by a pregnancyinduced increase in its biotransformation, the trend towards increased renal elimination of OH-BUP may overshadow any corresponding change in the hydroxylation activity of CYP2B. The transplacental transfer of BUP and its metabolites also contributes to the total clearance of BUP from maternal plasma, as BUP, OH-BUP, TB, and EB were all detected in neonatal plasma after delivery. Based on previous in vitro data, the metabolism of BUP to TB and EB within baboon placenta is expected to be only a minor factor affecting the overall clearance of BUP (Wang et al., 2011) . 
